Serial Number | 79331562 |
Word Mark | WUXI VACCINES |
Filing Date | Tuesday, July 20, 2021 |
Status | 700 - REGISTERED |
Status Date | Tuesday, February 28, 2023 |
Registration Number | 6988097 |
Registration Date | Tuesday, February 28, 2023 |
Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
Published for Opposition Date | Tuesday, December 13, 2022 |
Goods and Services | Custom assembling of materials for others being custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, and vaccines by pharmaceutical compounders; custom manufacture of pharmaceuticals medical preparation; customized production service being custom manufacturing of pharmaceuticals; customized production service being custom manufacturing of vaccines; medicinal materials processing being custom manufacture of pharmaceuticals; processing and treatment of chemical reagents, namely, custom production of reagents for scientific or medical research use; processing of pharmaceutical materials for others being processing of medicinal plants and biological organisms; processing of biomedical materials for others being biomanufacturing for others in the nature of manufacturing of pharmaceuticals and vaccines using biological organisms in the manufacturing process; processing of chemical materials for vaccine production being custom manufacture of vaccines |
Description of Mark | The mark consists of a stylized representation of a spiral and shaded circle next to four Chinese characters above the wording "WUXI VACCINES". |
Transliteration Statement | The non-Latin characters in the mark transliterate to "YAO" "MING" "HAI" "DE" which mean "MEDICINE" "BRIGHT" "SEA" and "MORALITY" individually in English. The combination of the non-Latin characters has no meaning in a foreign language. |
Disclaimer with Predetermined Text | "WUXI VACCINES" AND THE NON-LATIN CHARACTER THAT TRANSLITERATES TO "YAO" |
Goods and Services | Development of new products for others; development of pharmaceutical preparations and medicines being research and development of new products for others; scientific research; medicine research services; research and development of new products; consulting services in the field of information technology development; biochemical research and analysis; biomedical research service; development of pharmaceutical preparations and medicines being research and development of new products for others; research and development of pharmaceuticals being research and development of new products for others |
International Class | 040 - Treatment of materials. |
US Class Codes | 100, 103, 106 |
Class Status Code | 6 - Active |
Class Status Date | Friday, January 21, 2022 |
Primary Code | 040 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, January 21, 2022 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Shanghai Vaccines Co., Ltd. |
Party Type | 30 - Original Registrant |
Legal Entity Type | 16 - Limited Liability Company |
Address | CN |
Party Name | Shanghai Vaccines Co., Ltd. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | CN |
Party Name | Shanghai Vaccines Co., Ltd. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | CN |
Event Date | Event Description |
Sunday, June 25, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
Friday, June 2, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
Friday, June 2, 2023 | FINAL DISPOSITION PROCESSED |
Sunday, May 28, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
Tuesday, February 28, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
Tuesday, February 28, 2023 | REGISTERED-PRINCIPAL REGISTER |
Wednesday, December 21, 2022 | NOTIFICATION PROCESSED BY IB |
Tuesday, December 13, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, December 13, 2022 | PUBLISHED FOR OPPOSITION |
Tuesday, November 29, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
Wednesday, November 23, 2022 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
Wednesday, November 23, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Wednesday, November 9, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Monday, November 7, 2022 | EXAMINER'S AMENDMENT ENTERED |
Monday, November 7, 2022 | ASSIGNED TO LIE |
Monday, November 7, 2022 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Monday, November 7, 2022 | EXAMINERS AMENDMENT E-MAILED |
Monday, November 7, 2022 | EXAMINERS AMENDMENT -WRITTEN |
Wednesday, November 2, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, November 2, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Wednesday, November 2, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Friday, September 30, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Friday, September 30, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Friday, September 30, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Friday, September 30, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Friday, September 30, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Monday, June 13, 2022 | REFUSAL PROCESSED BY IB |
Tuesday, May 24, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
Tuesday, May 24, 2022 | REFUSAL PROCESSED BY MPU |
Friday, April 15, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
Thursday, April 14, 2022 | NON-FINAL ACTION WRITTEN |
Wednesday, April 13, 2022 | ASSIGNED TO EXAMINER |
Tuesday, January 25, 2022 | APPLICATION FILING RECEIPT MAILED |
Friday, January 21, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Thursday, January 20, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |